AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33105701 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 19
Study 35332853 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment (NPA) with feedback
Number of subjects: 71
Study 35332853 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment control group
Number of subjects: 71
Study 34248926 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0
Study 32475445 — intervention group
Group type: COMPARATOR
Intervention: Fast-growing strain (B)
Number of subjects: 100
Study 32475445 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-growing strains (D, H, M)
Number of subjects: 100
Study 32475445 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-growing strain (E)
Number of subjects: 100
Study 36347059 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral combination regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) for 24 weeks
Number of subjects: 4446
Study 36347059 — intervention group
Group type: COMPARATOR
Intervention: Early treatment of anal high-grade squamous intraepithelial lesions
Number of subjects: 4446
Study 32692300 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning-based Automatic Detection Algorithm (DLAD)
Number of subjects: 117
Study 32692300 — intervention group
Group type: COMPARATOR
Intervention: No DLAD
Number of subjects: 117
Study 36222612 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute head-neck cooling for ≥45 minutes in addition to standard SRC management
Number of subjects: 132
Study 36222612 — intervention group
Group type: COMPARATOR
Intervention: Standard SRC management (control group)
Number of subjects: 132
Study 36222612 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute head-neck cooling
Number of subjects: 132
Study 34491013 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Stamp Technique (MST)
Number of subjects: 30
Study 34491013 — intervention group
Group type: COMPARATOR
Intervention: Conventional Technique (CT)
Number of subjects: 30
Study 32696227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 5% dextrose in 0.9% normal saline (according to weight-based maintenance rate)
Number of subjects: 290
Study 32696227 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (0.15 mg·kg−1 iv) and ondansetron (0.05 mg·kg−1 iv)
Number of subjects: 290
Study 36213959 — intervention group
Group type: COMPARATOR
Intervention: Home-based care and Routine clinic-based care
Number of subjects: 240
Study 34218513 — intervention group
Group type: EXPERIMENTAL
Intervention: PERN facilitated international collaborative research
Number of subjects: 0
Study 34218513 — intervention group
Group type: EXPERIMENTAL
Intervention: PERN's network infrastructure
Number of subjects: 0
Study 34218513 — intervention group
Group type: EXPERIMENTAL
Intervention: PERN's goals
Number of subjects: 0
Study 32829943 — intervention group
Group type: EXPERIMENTAL
Intervention: Home kinematic training (KT) for 4 weeks using laser or virtual reality
Number of subjects: 79
Study 32829943 — intervention group
Group type: EXPERIMENTAL
Intervention: Home kinematic training (KT)
Number of subjects: 79
Study 35386725 — intervention group
Group type: EXPERIMENTAL
Intervention: ANGEL-6000 EEG depth monitor
Number of subjects: 60
Study 35386725 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard anesthetic monitoring)
Number of subjects: 60
Study 35386725 — intervention group
Group type: COMPARATOR
Intervention: Both groups received the same anesthetic drugs
Number of subjects: 60
Study 34224519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral decubitus position
Number of subjects: 28
Study 34224519 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 28
Study 33825118 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-only strategy with subsequent frozen embryo transfer (n = 20)
Number of subjects: 40
Study 33825118 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryo transfer (n = 20)
Number of subjects: 40
Study 32126977 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg oral daily for 6 months
Number of subjects: 15
Study 32126977 — intervention group
Group type: COMPARATOR
Intervention: IFN-β 1b 250 μg subcutaneous every other day for 6 months
Number of subjects: 15
Study 34371162 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Living Every Day (ALED) and age-relevant health education information
Number of subjects: 300
Study 34371162 — intervention group
Group type: EXPERIMENTAL
Intervention: ALED program in combination with Our Voice (neighborhood-level citizen science intervention)
Number of subjects: 300
Study 32077891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks) starting 2 to 6 weeks after chemoradiotherapy
Number of subjects: 21
Study 32077891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (100 mg IV every 3 weeks) starting day 29 of chemoradiotherapy
Number of subjects: 21
Study 32077891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks) starting day 29 of chemoradiotherapy
Number of subjects: 21
Study 32077891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (100 mg IV every 3 weeks) starting day 1 of chemoradiotherapy
Number of subjects: 21
Study 32077891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks) starting day 1 of chemoradiotherapy
Number of subjects: 21
Study 32077891 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety expansion cohort with cohort 5 regimen
Number of subjects: 21
Study 32077891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (at least 1 dose)
Number of subjects: 21
Study 32077891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (at least 2 doses)
Number of subjects: 21
Study 32077891 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-related adverse events
Number of subjects: 21
Study 33337437 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology intervention
Number of subjects: 256
Study 32199184 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Skills Training (SST)
Number of subjects: 62
Study 32199184 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 36169496 — intervention group
Group type: EXPERIMENTAL
Intervention: Early piezocision
Number of subjects: 40
Study 36169496 — intervention group
Group type: EXPERIMENTAL
Intervention: Late piezocision
Number of subjects: 40
Study 36169496 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision
Number of subjects: 40
Study 36169496 — intervention group
Group type: COMPARATOR
Intervention: No piezocision
Number of subjects: 40
Study 36169496 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision (early and late)
Number of subjects: 40
Study 36169496 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study 33891230 — intervention group
Group type: EXPERIMENTAL
Intervention: saccharide preload (26 kcal)
Number of subjects: 17
Study 33891230 — intervention group
Group type: COMPARATOR
Intervention: placebo capsules
Number of subjects: 17
Study 35468266 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based outpatient physical therapy intervention delivered six weeks after TKR.
Number of subjects: 180
Study 33999707 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dronabinol
Number of subjects: 24
Study 33999707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32134802 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimo DDS 132 µg
Number of subjects: 113
Study 32134802 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimo DDS 264 µg
Number of subjects: 113
Study 32134802 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 113
Study 32134802 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimo DDS 132 µg and 264 µg
Number of subjects: 113
Study 35857131 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg kg−1)
Number of subjects: 20
Study 35857131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32816639 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (7.5-15 mg twice daily)
Number of subjects: 8
Study 32816639 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg)
Number of subjects: 8
Study 32816639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 35822542 — intervention group
Group type: EXPERIMENTAL
Intervention: High aerobic exercise-induced energy expenditures in energy balance (BAL)
Number of subjects: 10
Study 35822542 — intervention group
Group type: EXPERIMENTAL
Intervention: High aerobic exercise-induced energy expenditures in energy deficit (DEF)
Number of subjects: 10
Study 33118401 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint extract (40 drops mixed in 20 cc of tap water every 8 hours)
Number of subjects: 84
Study 33118401 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (40 drops mixed in 20 cc of tap water every 8 hours)
Number of subjects: 84
Study 36125472 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast cream, 0.3%
Number of subjects: 881
Study 32363765 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Loading (IML)
Number of subjects: 20
Study 32363765 — intervention group
Group type: COMPARATOR
Intervention: Conventional Loading (CL)
Number of subjects: 20
Study 32363765 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IML and CL
Number of subjects: 20
Study 36134506 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar fortified breads with galactomannan above coil overlap
Number of subjects: 12
Study 36134506 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar fortified breads with galactomannan below coil overlap
Number of subjects: 12
Study 36134506 — intervention group
Group type: COMPARATOR
Intervention: Wheat flour control bread
Number of subjects: 12
Study 33653385 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention including identification and screening of household contacts, referral of contacts with TB-suggestive symptoms, and household initiation of preventive therapy.
Number of subjects: 1500
Study 33653385 — intervention group
Group type: COMPARATOR
Intervention: Facility-based standard of care arm.
Number of subjects: 1500
Study 36209981 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with gemcitabine (1000mg/m2) and nab-Paclitaxel (125mg/m2) for 2 preoperative and 4 postoperative cycles (arm A)
Number of subjects: 127
Study 36209981 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with gemcitabine (1000mg/m2) and nab-Paclitaxel (125mg/m2) for 6 cycles (arm B)
Number of subjects: 127
Study 33813638 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Nd:YAG/Er:YAG laser therapy (test group)
Number of subjects: 22
Study 33813638 — intervention group
Group type: COMPARATOR
Intervention: Turned off laser therapy (control group)
Number of subjects: 22
Study 36207993 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating chitosan brush (OCB)
Number of subjects: 39
Study 36207993 — intervention group
Group type: COMPARATOR
Intervention: Titanium curettes (TC)
Number of subjects: 39
Study 33454262 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) scoring strategy
Number of subjects: 1083
Study 33454262 — intervention group
Group type: COMPARATOR
Intervention: Traditional risk factor-based prediction
Number of subjects: 1083
Study 33260151 — intervention group
Group type: COMPARATOR
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Number of subjects: 0
Study 35391634 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat‐ and moisture‐exchanging breathing device (HME)
Number of subjects: 23
Study 35391634 — intervention group
Group type: COMPARATOR
Intervention: No HME
Number of subjects: 23
Study 33124016 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal mouthguard
Number of subjects: 13
Study 33124016 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthguard with breathing channels
Number of subjects: 13
Study 33124016 — intervention group
Group type: COMPARATOR
Intervention: Control (no mouthguard)
Number of subjects: 13
Study 33220702 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessments based on PsAMRIS for heel enthesitis
Number of subjects: 0
Study 33220702 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifications to PsAMRIS scoring system
Number of subjects: 0
Study 35500975 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutonia
Number of subjects: 80
Study 35500975 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic Gymnastics
Number of subjects: 80
Study 35500975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 80
Study 35500975 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 80
Study 33176043 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (100 mg daily for 4 weeks)
Number of subjects: 16
Study 33176043 — intervention group
Group type: COMPARATOR
Intervention: Doxepin (10 mg daily for 4 weeks)
Number of subjects: 16
Study 34228123 — intervention group
Group type: EXPERIMENTAL
Intervention: StepCBT-I (web-based CBT-I for less severe insomnia, face-to-face CBT-I for more severe insomnia)
Number of subjects: 177
Study 34228123 — intervention group
Group type: COMPARATOR
Intervention: StanCBT-I (6 face-to-face CBT-I sessions)
Number of subjects: 177
Study 34228123 — intervention group
Group type: EXPERIMENTAL
Intervention: StepCBT-I
Number of subjects: 177
Study 33065822 — intervention group
Group type: EXPERIMENTAL
Intervention: PaRK intervention
Number of subjects: 355
Study 33065822 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard web-based educational factsheets)
Number of subjects: 355
Study 36233500 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic tinzaparin (4500 IU)
Number of subjects: 300
Study 36233500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate tinzaparin (100 IU/kg)
Number of subjects: 300
Study 36233500 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic tinzaparin (175 IU/kg)
Number of subjects: 300
Study 36233500 — intervention group
Group type: COMPARATOR
Intervention: All groups (Prophylactic, Intermediate, Therapeutic)
Number of subjects: 300
Study 36233500 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 300
Study 32723675 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day
Number of subjects: 16
Study 36064130 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich gel combined with conventional treatment and TCM
Number of subjects: 60
Study 36064130 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy and TCM
Number of subjects: 60
Study 34155984 — intervention group
Group type: EXPERIMENTAL
Intervention: Youper app (AI therapy)
Number of subjects: 4517
Study 34210720 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive therapeutic drug monitoring (TDM) arm with infliximab dosing optimised to target higher trough levels (TLI ≥ 25 μg/mL at week 2, ≥ 20 μg/mL at week 6, and ≥ 10 μg/mL during maintenance therapy)
Number of subjects: 138
Study 34210720 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing arm with conventional infliximab dosing (5 mg/kg at weeks 0, 2, and 6, and 5 mg/kg 8 weekly thereafter)
Number of subjects: 138
Study 33085686 — intervention group
Group type: EXPERIMENTAL
Intervention: Message about harmful chemicals
Number of subjects: 2801
Study 33085686 — intervention group
Group type: EXPERIMENTAL
Intervention: Message about uncertainty about ingredients
Number of subjects: 2801
Study 33085686 — intervention group
Group type: EXPERIMENTAL
Intervention: Message about distrust of big tobacco
Number of subjects: 2801
Study 33085686 — intervention group
Group type: EXPERIMENTAL
Intervention: Message about cost of vaping
Number of subjects: 2801
Study 33085686 — intervention group
Group type: COMPARATOR
Intervention: Control message (bottled water ad)
Number of subjects: 2801
Study 33357965 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean dietary intervention with moderate protein restriction
Number of subjects: 502
Study 33357965 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 502
Study 32004214 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed (Ra) with oxaliplatin (L‐OHP)
Number of subjects: 38
Study 32004214 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed (Ra) with cisplatin (DDP)
Number of subjects: 38
Study 32004214 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed (Ra) with mitomycin C (MMC)
Number of subjects: 38
Study 32004214 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 38
Study 35835256 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages promoting healthy lifestyle and activity monitor
Number of subjects: 31
Study 35835256 — intervention group
Group type: COMPARATOR
Intervention: No text message (comparison days)
Number of subjects: 31
Study 34186547 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) combined with petrolatum gauze
Number of subjects: 36
Study 34186547 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum gauze alone (Control)
Number of subjects: 36
Study 32017250 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (MBSR)
Number of subjects: 0
Study 32017250 — intervention group
Group type: COMPARATOR
Intervention: Health education attention control
Number of subjects: 0
Study 35745125 — intervention group
Group type: EXPERIMENTAL
Intervention: Shelf tag intervention indicating the Health Star Rating (HSR) of all packaged products that scored 4.5 or 5 stars, along with posters for fresh fruits and vegetables.
Number of subjects: 304
Study 35745125 — intervention group
Group type: COMPARATOR
Intervention: Control stores without the shelf tag intervention.
Number of subjects: 304
Study 35745125 — intervention group
Group type: EXPERIMENTAL
Intervention: Shelf tag intervention.
Number of subjects: 304
Study 36052470 — intervention group
Group type: EXPERIMENTAL
Intervention: Online learning using Moodle 2.9 for 90 minutes, followed by 2 hours of skill training.
Number of subjects: 78
Study 36052470 — intervention group
Group type: COMPARATOR
Intervention: Didactic lecture for 90 minutes, followed by 2 hours of skill training.
Number of subjects: 78
Study 33998949 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with 50% effectiveness
Number of subjects: 1117
Study 33998949 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with 95% effectiveness
Number of subjects: 1117
Study 35985196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligonol® supplementation (200 mg per day)
Number of subjects: 120
Study 35985196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin)
Number of subjects: 120
Study 34410982 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal water
Number of subjects: 174
Study 34410982 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 174
Study 34624157 — intervention group
Group type: EXPERIMENTAL
Intervention: Machined surface (MS) implant sites
Number of subjects: 24
Study 34624157 — intervention group
Group type: COMPARATOR
Intervention: Laser-microtextured surface (LMS) implant sites
Number of subjects: 24
Study 33509031 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous water irrigation (experimental group)
Number of subjects: 12
Study 33509031 — intervention group
Group type: COMPARATOR
Intervention: No water irrigation (static control group)
Number of subjects: 12
Study 33509031 — intervention group
Group type: COMPARATOR
Intervention: No water irrigation (dynamic control group)
Number of subjects: 12
Study 32168217 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose copper (175 mm) intrauterine contraceptive with a flexible nitinol frame
Number of subjects: 286
Study 35796019 — intervention group
Group type: EXPERIMENTAL
Intervention: NO2 reduction treatment (sham particle filtration and real NO2 scrubbing)
Number of subjects: 126
Study 35796019 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle filtration treatment (HEPA filter and sham NO2 scrubbing)
Number of subjects: 126
Study 35796019 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (sham particle filtration and sham NO2 scrubbing)
Number of subjects: 126
Study 32500753 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin in combination with bendamustine and rituximab (BR)
Number of subjects: 0
Study 32500753 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin-BR
Number of subjects: 0
Study 32500753 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin in combination with R-CHOP
Number of subjects: 0
Study 33331637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 40 mg orally, followed by 10 mg orally three times a day until 12 completed weeks of gestation or 1 week after bleeding stopped
Number of subjects: 406
Study 33331637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 33331637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Number of subjects: 406
Study 35144225 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized invitations from a physician
Number of subjects: 0
Study 35144225 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized invitations with information about peer screening behavior
Number of subjects: 0
Study 35144225 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized invitations with a labeled but unconditional financial incentive
Number of subjects: 0
Study 35144225 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal invitations with a conditional financial incentive
Number of subjects: 0
Study 35144225 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33333328 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP)
Number of subjects: 578
Study 33333328 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin or cisplatin plus pemetrexed (PP)
Number of subjects: 578
Study 33808079 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina supplementation (6 g per day)
Number of subjects: 24
Study 33808079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 36054253 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg daily plus montelukast 10 mg daily
Number of subjects: 108
Study 36054253 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg daily plus placebo
Number of subjects: 108